Episode 81
Kikiriki
7 February 2022
23 mins 39 secs
Tags
About this Episode
✓ Kako je američko udruženje pedijatara promenilo mišljenje o kikirikiju?
✓ Mogu li kliničke preporuke imati rok trajanja?
✓ Kako onkolozi preskaču agenciju za lekove?
Episode Links
- Early consumption of peanuts in infancy is associated with a low prevalence of peanut allergy - Journal of Allergy and Clinical Immunology — We demonstrate that Jewish children in the UK have a prevalence of PA that is 10-fold higher than that of Jewish children in Israel. This difference is not accounted for by differences in atopy, social class, genetic background, or peanut allergenicity. Israeli infants consume peanut in high quantities in the first year of life, whereas UK infants avoid peanuts. These findings raise the question of whether early introduction of peanut during infancy, rather than avoidance, will prevent the development of PA.
- Effect of Avoidance on Peanut Allergy after Early Peanut Consumption | NEJM — In a randomized trial, the early introduction of peanuts in infants at high risk for allergy was shown to prevent peanut allergy. In this follow-up study, we investigated whether the rate of peanut allergy remained low after 12 months of peanut avoidance among participants who had consumed peanuts during the primary trial (peanut-consumption group), as compared with those who had avoided peanuts (peanut-avoidance group).
- Circumcision Policy Statement | Pediatrics | American Academy of Pediatrics — All policy statements from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time.
- Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America — This document provides evidence-based clinical practice guidelines on the management of adult patients with community-acquired pneumonia.
- About The National Comprehensive Cancer Network® — The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of 31 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives.
- Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study | The BMJ — The NCCN frequently recommends beyond the FDA approved indications even for newer, branded drugs. The strength of the evidence cited by the NCCN supporting such recommendations is weak. Our findings raise concern that the NCCN justifies the coverage of costly, toxic cancer drugs based on weak evidence.